(5-甲基呋喃并[2,3-B]吡啶-2-基)甲醇 | 1228666-60-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡啶类
• 中文名称: (5-甲基呋喃并[2,3-B]吡啶-2-基)甲醇
• 英文名称: (5-Methylfuro[2,3-b]pyridin-2-yl)methanol
• CAS: 1228666-60-1
• 化学式: C₉H₉NO₂
• mdl: MFCD16628267
• 分子量: 163.17
• InChiKey: GIGQFINHHUTCAQ-UHFFFAOYSA-N

物化性质

• 沸点：
  310.7±37.0 °C(Predicted)
• 密度：
  1.258±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

文献信息

• Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide
  申请人：Psomagen, Inc.

  公开号：US11424006B2

  公开（公告）日：2022-08-23

  Embodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.

  方法和/或系统的实施方案可包括向患有与 TMA、TMAO 和/或其衍生物中的至少一种相关的一种或多种疾病的患者施用治疗有效量的化合物，以影响抑制与一组微生物类群中至少一个类群的微生物相关的一种或多种 CutC 酶和/或 CntA 酶。
• TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE
  申请人：Psomagen, Inc.

  公开号：EP3668494A1

  公开（公告）日：2020-06-24
• RIESKE-TYPE OXYGENASE/REDUCTASE TARGETED DRUGS FOR DIAGNOSTIC AND TREATMENT OF DISEASES
  申请人：uBiome, Inc.

  公开号：US20190050525A1

  公开（公告）日：2019-02-14

  Embodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.
• [EN] TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE<br/>[FR] MÉDICAMENTS CIBLÉS ASSOCIÉS À LA TRIMÉTHYLAMINE ET/OU À LA TRIMÉTHYLAMINE-N-OXYDE
  申请人：UBIOME INC

  公开号：WO2019036507A1

  公开（公告）日：2019-02-21

  Embodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.